No quarterly revenue total was found in DRUGS MADE IN AMERICA ACQUISITION CORP.'s SEC filings.
Drugs Made In America Acquisition Corp. (DMAA) files with the SEC under industry code 6770, Blank Checks.
Revenue
—
Net income
$1.73M
-24.5% vs year-ago quarter
Operating cash flow
$-244,607
-129.3% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
24.28M
-27.6% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- DMAA (Nasdaq), DMAAR (Nasdaq), DMAAU (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2028614
Other Blank Checks companies
- Drugs Made In America Acquisition II Corp. DMII
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$136,934 | -$143,301 | -$2.1M | -$263,703 | -$131,919 |
| Net income | $1.7M | $2.0M | $212,958 | $2.2M | $2.3M |
| Operating cash flow | -$244,607 | -$91,250 | -$125,180 | -$56,108 | -$106,655 |
| Total assets | $146.9M | $242.0M | $239.9M | $237.6M | $235.2M |
| Total liabilities | $9.1M | $7.4M | $7.3M | $7.4M | $7.2M |
| Stockholders' equity | -$7.4M | -$7.4M | -$7.3M | -$7.3M | -$7.2M |
| Cash and investments | $20,280 | $14,887 | $6,137 | $717 | $822 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
Oct 21, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 14, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 20, 2026 | Jul 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
May 5, 2026 | Apr 29, 2026 |
All 80 Drugs Made In America Acquisition Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.